Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
AssigneesInstitut National De La Sante Et De La Recherche Medicale (Inserm), Centre National de la Recherche Scientifique (CNRS), Assistance Publique-Hopitaux de Paris, Universite De Paris, Imagine Ltd.
InventorsLaurence LEGEAI-MALLET, Arnold MUNNICH, Patricia BUSCA, Florent BARBAULT
Life of this patent
Estimating the term…
Abstract
The present invention relates to the treatment or prevention of skeletal disorders, at particular skeletal diseases, developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FGFR3), in particular by expression of a constitutively activated mutant of FGFR3.
Claims2
A method for treating or preventing a FGFR3-related skeletal disease which comprises the step of administering at least one antagonist of the FGFR3 tyrosine kinase receptor of formula:
- or a composition comprising such an antagonist, to a subject in need thereof.
Dependencies are inferred from the claim text.